Desmopressin vs Cotadutide
Head-to-head comparison of Desmopressin (1-Deamino-8-D-arginine vasopressin) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Desmopressin | Cotadutide |
|---|---|---|
| Category | Cognitive Enhancement | Weight Management |
| Full Name | 1-Deamino-8-D-arginine vasopressin | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 1069.22 Da | ~4,700 Da |
| Half-Life | 1.5-3 hours | Approximately 24 hours |
| Amino Acids | 9 | 37 |
| Typical Dose | 10-40 mcg intranasal | 0.3-3 mg daily in clinical studies |
| Route | Intranasal/Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 35 | 18 |
| Research Status | Clinical | Clinical |
Desmopressin Benefits
- ✓memory consolidation
- ✓reduced pressor burden
- ✓recall support
- ✓short-term learning
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Desmopressin Dosing
intranasal research dosing|10-40 mcg or IU-equivalent studies|single-dose protocols
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Desmopressin Side Effects
- ⚠hyponatremia
- ⚠headache
- ⚠nasal irritation
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Desmopressin
The literature is mixed, but desmopressin has shown memory-related effects in selected populations and experimental paradigms. Its cognitive effects are usually discussed as a vasopressin-pathway probe rather than a primary nootropic.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.